Issue link: https://www.e-digitaleditions.com/i/1532011
Inhalation February 2025 19 PFAS-free MDI canister coating Big changes are coming, especially related to future per- and polyfluoroalkyl substances (PFAS) bans. Biomerics can help you stay out in front of them with our new, patent pending, 100% PFAS-free metered dose inhaler (MDI) canister coating. So far, pharma- ceutical test results show equivalency to current PFAS coatings. Please reach out to us and let us know how we can support your MDI projects. Biomerics US: +1 540 246-1930 rchurchill@biomerics.com www.biomerics.com Engineering design services MKON is an engineering design firm with extensive experience in computational fluid dynamics (CFD) and finite element analysis (FEA), solid modeling of product and package designs, and valve and other injection-molded components. We have solved con- tainer/closure leakage problems for our clients, often leading to patent protection. One CFD solution allowed a client into clinical trials with a generic epi- nephrine formulation packaged under extremely low oxygen levels on existing equipment. Our proven track record is exemplified by our 28+ patents. Let us help you with your difficult design or production issues. MKON, LLC US: +1 512 707-9260 info@mkonllc.com www.mkonllc.com Respiratory drug product development software Fusion Process Development (FPD) for respiratory drug product R&D is the perfect companion mod- ule to Fusion Inhaler Testing (FIT) for QC. FPD has automated Design of Experiments (DoE) and data modeling for formulation and process R&D. FPD enables you to create companion testing designs for your formulation and device design studies with full bi-directional Chromatography Data Software (CDS) testing automation. Automated CDS testing and data retrieval includes handling of complex data from cas- cade impaction testing and dissolution testing. And FPD operates under full regulatory compliance to maintain data integrity. S-Matrix ® US: +1 707 441-0406 sales@smatrix.com www.smatrix.com Best practices, new tests and technologies Partnering with Proveris Laboratories ensures use of industry best practices, the expertise to interpret results, and access to new technologies to accelerate orally inhaled and nasal drug product (OINDP) devel- opment. e Proveris by Design™ process, employed by Proveris Laboratories, creates the shortest path to submission for clients. By regularly integrating new tests and technologies such as spray velocity, evapora- tion fraction and human-realistic regional deposition, clients evaluate products according to the most cur- rent regulatory guidance documents and adapt devel- opment needs for product success. Learn about these techniques and see published data on the Proveris website: https://bit.ly/4bPeLyT. Proveris Laboratories US: +1 508 460-8822 contactus@proveris.com www.proveris.com